Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Complications of Diabetes Mellitus01:22

Complications of Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Same day discharge colon surgery: is it financially worth it?

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2024
Same author

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study.

European journal of gynaecological oncology·2023
Same author

Beyond enhanced recovery after surgery (ERAS): Evolving minimally invasive colectomy from multi-day admissions to same-day discharge.

American journal of surgery·2023
Same author

Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?

Medical hypotheses·2020
Same author

An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in <i>MLL1</i>-rearranged acute myeloid leukemia in mice.

The Journal of biological chemistry·2020

Related Experiment Video

Updated: Jun 25, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Diabetic retinopathy: A comprehensive review.

Chirag A Shah1

  • 1Department of Life Sciences, Accelaire Consulting and Research Pvt. Ltd., Pune-411 037, India. chiirag@gmail.com

Indian Journal of Medical Sciences
|March 7, 2009
PubMed
Summary

Diabetic retinopathy (DR) management involves metabolic control, laser therapy, and vitrectomy. Emerging pharmacological treatments show promise for preventing blindness, emphasizing early detection through timely eye exams.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic retinopathy (DR) is a leading cause of blindness globally.
  • Effective management includes metabolic control, blood pressure regulation, laser photocoagulation, and vitrectomy.
  • Current treatments face limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To provide a comprehensive review of diabetic retinopathy (DR).
  • To emphasize the pathophysiology and management strategies for DR.
  • To highlight emerging pharmacological therapies for DR.

Main Methods:

  • Literature review focusing on diabetic retinopathy pathophysiology and management.
  • Analysis of current and emerging treatment modalities.

More Related Videos

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats
07:41

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Published on: October 23, 2020

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Related Experiment Videos

Last Updated: Jun 25, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats
07:41

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Published on: October 23, 2020

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

  • Emphasis on the importance of early detection and regular eye examinations for diabetic patients.

    • Main Results:

    • Tight metabolic and blood pressure control significantly reduces DR risk and progression.
    • Laser photocoagulation and vitrectomy are crucial for preventing severe vision loss.
    • Promising pharmacological therapies include protein kinase C inhibitors, steroids, VEGF inhibitors, ACE inhibitors (e.g., candesartan), and growth hormone inhibitors.

    Conclusions:

    • Early identification of DR through timely eye examinations is critical for successful treatment outcomes.
    • A combination of established and novel therapies offers potential to prevent blindness in diabetic patients.
    • Continued research into pharmacological interventions is essential to overcome current treatment limitations.